[Form 4] ARTIVION, INC. Insider Trading Activity

Rhea-AI Filing Summary

Artivion, Inc. (AORT) senior vice president of Clinical & MD Affairs Marshall Stanton reported insider transactions in company stock. On 11/20/2025, he sold 11,888 shares of common stock at a weighted average price of $44.14 per share, and in separate transactions sold additional shares at weighted average prices of $44.315 and $44.278 per share. The sales were reported as open-market dispositions.

On the same date, Stanton exercised stock options to buy 2,033 shares at an exercise price of $18.44 per share and 1,355 shares at an exercise price of $11.03 per share, then sold the corresponding shares. Following these transactions, he reported beneficial ownership of 44,753 shares of Artivion common stock held directly, along with vested and unexercised stock options covering 20,301 shares at $18.44 and 27,075 shares at $11.03.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stanton Marshall S.

(Last) (First) (Middle)

1655 ROBERTS BLVD., NW

(Street)

KENNESAW GA 30144

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Clinical & MD Affair

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		S		11,888	D	$44.14(1)	44,753	D
Common Stock	11/20/2025		M		2,033	A	$18.44	46,786	D
Common Stock	11/20/2025		S		2,033	D	$44.315(2)	44,753	D
Common Stock	11/20/2025		M		1,355	A	$11.03	46,108	D
Common Stock	11/20/2025		S		1,355	D	$44.278(3)	44,753	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$18.44	11/20/2025		M			2,033	02/23/2023(4)	02/23/2029	Common Stock	2,033	$0	20,301	D
Stock Options (Right to buy)	$11.03	11/20/2025		M			1,355	11/08/2023(5)	11/08/2029	Common Stock	1,355	$0	27,075	D

Explanation of Responses:

1. Reflects weighted average price. Range of prices were between $43.92 to $44.49. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

2. Reflects weighted average price. Range of prices were between $44.26 to $44.44. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Reflects weighted average price. Range of prices were between $44.26 to $44.35. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023.

5. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023.

Remarks:

	/s/ Marshall Stanton	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Artivion (AORT) report for Marshall Stanton?

Artivion reported that Marshall Stanton, its SVP of Clinical & MD Affairs, executed option exercises and open-market sales of Artivion common stock on 11/20/2025, as disclosed on a Form 4.

How many Artivion (AORT) shares did the executive sell on 11/20/2025?

The filing shows that 11,888 shares of Artivion common stock were sold at a weighted average price of $44.14 per share, with additional sales executed at weighted average prices of $44.315 and $44.278 per share.

What stock options did the Artivion (AORT) executive exercise?

On 11/20/2025, the executive exercised stock options to buy 2,033 shares at an exercise price of $18.44 per share and 1,355 shares at an exercise price of $11.03 per share, each for Artivion common stock.

What is the executive’s remaining Artivion (AORT) stock ownership after the transactions?

After the reported transactions, the executive directly beneficially owned 44,753 shares of Artivion common stock, according to the Form 4.

How many Artivion (AORT) stock options does the executive still hold?

Following the transactions, the filing reports 20,301 stock options with an exercise price of $18.44 per share and 27,075 stock options with an exercise price of $11.03 per share still beneficially owned.

What do the weighted average sale prices mean in the Artivion (AORT) Form 4?

The Form 4 notes that the reported sale prices, such as $44.14, $44.315, and $44.278, are weighted average prices over price ranges, and that detailed breakdowns by price level will be provided upon request to the Commission staff, the issuer, or a security holder.